Brokerages Set Replimune Group, Inc. (NASDAQ:REPL) PT at $16.80

Shares of Replimune Group, Inc. (NASDAQ:REPL) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $16.80.

Several equities research analysts have recently commented on REPL shares. Roth Mkm began coverage on Replimune Group in a report on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a report on Monday, September 16th. JPMorgan Chase & Co. lifted their target price on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. Finally, Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th.

Insider Activity at Replimune Group

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the sale, the chief financial officer now directly owns 101,057 shares in the company, valued at $1,028,760.26. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in REPL. Creative Planning raised its holdings in shares of Replimune Group by 28.7% in the 3rd quarter. Creative Planning now owns 21,047 shares of the company’s stock worth $231,000 after buying an additional 4,699 shares in the last quarter. SG Americas Securities LLC bought a new stake in Replimune Group in the third quarter valued at $251,000. Point72 DIFC Ltd bought a new stake in Replimune Group in the second quarter valued at $57,000. Cubist Systematic Strategies LLC raised its stake in Replimune Group by 282.2% during the second quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock worth $650,000 after acquiring an additional 53,313 shares in the last quarter. Finally, Algert Global LLC lifted its holdings in shares of Replimune Group by 5.4% during the second quarter. Algert Global LLC now owns 84,033 shares of the company’s stock valued at $756,000 after acquiring an additional 4,340 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Stock Performance

NASDAQ:REPL opened at $11.53 on Friday. The company has a 50-day moving average of $10.78 and a 200-day moving average of $8.86. The firm has a market cap of $787.73 million, a price-to-earnings ratio of -3.53 and a beta of 1.21. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16. Replimune Group has a twelve month low of $4.92 and a twelve month high of $15.33.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.10. Analysts forecast that Replimune Group will post -3.11 earnings per share for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.